奥密克戎变异株流行期间德国针对重症 COVID-19 的疫苗效力：COViK 研究结果。

Vaccine effectiveness against severe COVID-19 during the Omicron wave in Germany: results from the COViK study.

机构信息

Department for Infectious Disease Epidemiology, Immunization Unit, Robert Koch Institute, Berlin, Germany.

Department for Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany.

出版信息

Infection. 2023 Aug;51(4):1093-1102. doi: 10.1007/s15010-023-02012-z. Epub 2023 Mar 13.

PURPOSE

COViK, a prospective hospital-based multicenter case-control study in Germany, aims to assess the effectiveness of COVID-19 vaccines against severe disease. Here, we report vaccine effectiveness (VE) against COVID-19-caused hospitalization and intensive care treatment during the Omicron wave.

METHODS

We analyzed data from 276 cases with COVID-19 and 494 control patients recruited in 13 hospitals from 1 December 2021 to 5 September 2022. We calculated crude and confounder-adjusted VE estimates.

RESULTS

21% of cases (57/276) were not vaccinated, compared to 5% of controls (26/494; p < 0.001). Confounder-adjusted VE against COVID-19-caused hospitalization was 55.4% (95% CI: 12-78%), 81.5% (95% CI: 68-90%) and 95.6% (95%CI: 88-99%) after two, three and four vaccine doses, respectively. VE against hospitalization due to COVID-19 remained stable up to one year after three vaccine doses.

CONCLUSION

Three vaccine doses remained highly effective in preventing severe disease and this protection was sustained; a fourth dose further increased protection.

目的

COViK 是一项在德国进行的前瞻性医院多中心病例对照研究，旨在评估 COVID-19 疫苗对严重疾病的有效性。在这里，我们报告了在奥密克戎（Omicron）浪潮期间 COVID-19 疫苗对住院和重症监护治疗的有效性（VE）。

方法

我们分析了 2021 年 12 月 1 日至 2022 年 9 月 5 日期间在 13 家医院招募的 276 例 COVID-19 病例和 494 例对照患者的数据。我们计算了粗 VE 和混杂因素调整后的 VE 估计值。

结果

21%（57/276）的病例未接种疫苗，而 5%（26/494）的对照未接种疫苗（p<0.001）。混杂因素调整后的 COVID-19 导致住院的 VE 分别为 55.4%（95%CI：12-78%）、81.5%（95%CI：68-90%）和 95.6%（95%CI：88-99%），分别在接种两、三、四剂疫苗后。接种三剂疫苗后一年，预防 COVID-19 住院的 VE 仍然稳定。